NASDAQ · Biotechnology

Coya Therapeutics, Inc. (COYA) Stock

$4.95 -0.80% NASDAQ: COYA Healthcare

Valuation

MetricValue
Price$4.95
Market Cap$116.11M
P/E Ratio-4.53
P/B Ratio2.65
P/S Ratio14.19
EPS (TTM)$0.00
52-Week High$7.75
52-Week Low$3.71
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-0.20%
ROA-0.05%
ROCE-0.05%
Gross Margin99.79%
Operating Margin-2.77%
Net Margin-270.22%
Debt/Equity0.00
Current Ratio8.33

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$6.0M$4.0M$8.0M
Operating Profit$-5.0M$-10.0M$-8.0M$-17.0M$-20.0M
Net Profit$-5.0M$-12.0M$-8.0M$-15.0M$-21.0M
EPS$-0.74$-1.23$-0.79$-0.98$-1.27
Op Margin——-131.7%-485.4%-255.1%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$5.0M$8.0M$41.0M$44.0M$50.0M
Total Liabilities$1.0M$17.0M$6.0M$5.0M$7.0M
Cash$4.0M$6.0M$33.0M$38.0M$47.0M
Borrowings$0$13.0M$0$0$0

Latest News

Is Coya Therapeutics, Inc. (COYA) Stock Outpacing Its Medical Peers This Year? Zacks · Jun 30, 2026 Coya Therapeutics to Present ALSTARS Trial Design at the ENCALS 2026 Meeting Business Wire · Jun 18, 2026 Coya Therapeutics to Host Virtual Webinar on the Intersection of Repetitive Head Trauma, Brain Inflammation and Neurodegenerative Disease Business Wire · Jun 15, 2026 Coya Therapeutics Says Phase 2 ALS Study Enters Blinded Extension Phase MT Newswires · Jun 8, 2026 Coya Therapeutics Announces the First Cohort of Patients in the ALSTARS Trial Have Begun the Blinded Active-Treatment Extension Phase Business Wire · Jun 8, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-4.0M$-7.0M$-11.0M$-10.0M$-11.0M
Investing Cash Flow$0$-1.0M$-1.0M$0$-1.0M
Financing Cash Flow$0$-1.0M$0$2.0M$0
Net Cash Flow$-4.0M$2.0M$27.0M$6.0M$8.0M
Free Cash Flow$-4.0M$-7.0M$-11.0M$-10.0M$-11.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.42
EV / EBITDA1951.35
FCF Yield-12026.07%
Quick Ratio13.40
Interest Coverage0.00
Return 1Y-20.33%
Return 3Y20.20%
Return 5Y—

Ownership

Insiders Held14.69%
Institutions Held35.37%
Institutions Float Held41.46%
Institutional HolderSharesReport Date
DME Capital Management, LP2,335,5402026-03-31
AIGH Capital Management LLC975,4042026-03-31
Vanguard Capital Management LLC844,9132026-03-31
Alyeska Investment Group, L.p.800,0002026-03-31
Prosight Management, Lp420,3602026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $336.64 -1.11% 38.93 $4.94T 0.32%
MSFTMicrosoft Corporation $535.07 +2.38% 28.68 $3.97T 0.76%
GOOGLAlphabet Inc. $351.66 +0.97% 16.94 $4.26T 0.26%
AMZNAmazon.com, Inc. $262.43 +3.29% 19.82 $2.82T 0.00%
METAMeta Platforms, Inc. $718.67 -0.31% 27.93 $1.83T 0.28%

About Coya Therapeutics, Inc.

Coya Therapeutics, Inc. is led by CEO Arun Swaminathan, employs 8 people, headquartered in US, publicly traded since 2022.

Coya Therapeutics, Inc. (COYA) stock trades at $4.95 with a market capitalization of $116.11M. The stock is valued at a price-to-earnings (P/E) ratio of -4.53, price-to-book of 2.65, price-to-sales of 14.19. Over the past 52 weeks the stock has ranged between $3.71 and $7.75, and currently trades 36.1% below its 52-week high.

On profitability, Coya Therapeutics, Inc. generates a return on equity (ROE) of -0.20%, return on capital employed of -0.05%, an operating margin of -2.77%, a net profit margin of -270.22%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides